Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer

Mark S. Walker, Damon J. Vidrine, Ellen R. Gritz, Randy J. Larsen, Yan Yan, Ramaswamy Govindan, Edwin B. Fisher

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Background: Non-small-cell lung cancer patients who continue to smoke after cancer diagnosis are more likely to experience disease recurrence, decreased treatment efficacy, and treatment complications. Despite this, many continue to smoke, with estimates ranging from 13% to -60%. Methods: Participants were 154 early-stage, non-small-cell lung cancer patients who had smoked within 3 months before surgery. Patients were followed for 12 months after surgery to assess smoking status and duration of continuous abstinence after surgery. Predictors included medical, smoking history, psychosocial, and demographic characteristics. Results: At some point after surgery, 42.9% of patients smoked; at 12 months after surgery, 36.9% were smoking. Sixty percent of patients who lapsed did so during the first 2 months after surgery. Smoking at follow-up was predicted by shorter quit duration before surgery, more intense Appetitive cravings (expectation of pleasure from smoking), lower income, and having a higher level of education. Time until the first smoking lapse was predicted by shorter quit duration before surgery, more intense Appetitive cravings to smoke, and lower income. Among those who lapsed, greater delay before the lapse was associated with abstinence at the 12-month follow-up assessment. Conclusions: Nearly half of non-small-cell lung cancer patients return to smoking after surgery if they have recent smoking histories. Most initial lapses happen within 2 months and occur in response to more recent smoking and more intense cravings. Findings suggest that interventions to prevent relapse should target those who wait until cancer surgery to quit smoking and should be started as soon as possible after treatment.

Original languageEnglish (US)
Pages (from-to)2370-2377
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Non-Small Cell Lung Carcinoma
Smoking
Recurrence
Smoke
Therapeutics
Pleasure
Neoplasms
History
Demography
Education

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Walker, M. S., Vidrine, D. J., Gritz, E. R., Larsen, R. J., Yan, Y., Govindan, R., & Fisher, E. B. (2006). Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiology Biomarkers and Prevention, 15(12), 2370-2377. https://doi.org/10.1158/1055-9965.EPI-06-0509

Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. / Walker, Mark S.; Vidrine, Damon J.; Gritz, Ellen R.; Larsen, Randy J.; Yan, Yan; Govindan, Ramaswamy; Fisher, Edwin B.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 12, 01.12.2006, p. 2370-2377.

Research output: Contribution to journalArticle

Walker, MS, Vidrine, DJ, Gritz, ER, Larsen, RJ, Yan, Y, Govindan, R & Fisher, EB 2006, 'Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 12, pp. 2370-2377. https://doi.org/10.1158/1055-9965.EPI-06-0509
Walker, Mark S. ; Vidrine, Damon J. ; Gritz, Ellen R. ; Larsen, Randy J. ; Yan, Yan ; Govindan, Ramaswamy ; Fisher, Edwin B. / Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 12. pp. 2370-2377.
@article{2f98683f81c945c38e17da58f653312d,
title = "Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer",
abstract = "Background: Non-small-cell lung cancer patients who continue to smoke after cancer diagnosis are more likely to experience disease recurrence, decreased treatment efficacy, and treatment complications. Despite this, many continue to smoke, with estimates ranging from 13{\%} to -60{\%}. Methods: Participants were 154 early-stage, non-small-cell lung cancer patients who had smoked within 3 months before surgery. Patients were followed for 12 months after surgery to assess smoking status and duration of continuous abstinence after surgery. Predictors included medical, smoking history, psychosocial, and demographic characteristics. Results: At some point after surgery, 42.9{\%} of patients smoked; at 12 months after surgery, 36.9{\%} were smoking. Sixty percent of patients who lapsed did so during the first 2 months after surgery. Smoking at follow-up was predicted by shorter quit duration before surgery, more intense Appetitive cravings (expectation of pleasure from smoking), lower income, and having a higher level of education. Time until the first smoking lapse was predicted by shorter quit duration before surgery, more intense Appetitive cravings to smoke, and lower income. Among those who lapsed, greater delay before the lapse was associated with abstinence at the 12-month follow-up assessment. Conclusions: Nearly half of non-small-cell lung cancer patients return to smoking after surgery if they have recent smoking histories. Most initial lapses happen within 2 months and occur in response to more recent smoking and more intense cravings. Findings suggest that interventions to prevent relapse should target those who wait until cancer surgery to quit smoking and should be started as soon as possible after treatment.",
author = "Walker, {Mark S.} and Vidrine, {Damon J.} and Gritz, {Ellen R.} and Larsen, {Randy J.} and Yan Yan and Ramaswamy Govindan and Fisher, {Edwin B.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1158/1055-9965.EPI-06-0509",
language = "English (US)",
volume = "15",
pages = "2370--2377",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer

AU - Walker, Mark S.

AU - Vidrine, Damon J.

AU - Gritz, Ellen R.

AU - Larsen, Randy J.

AU - Yan, Yan

AU - Govindan, Ramaswamy

AU - Fisher, Edwin B.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Background: Non-small-cell lung cancer patients who continue to smoke after cancer diagnosis are more likely to experience disease recurrence, decreased treatment efficacy, and treatment complications. Despite this, many continue to smoke, with estimates ranging from 13% to -60%. Methods: Participants were 154 early-stage, non-small-cell lung cancer patients who had smoked within 3 months before surgery. Patients were followed for 12 months after surgery to assess smoking status and duration of continuous abstinence after surgery. Predictors included medical, smoking history, psychosocial, and demographic characteristics. Results: At some point after surgery, 42.9% of patients smoked; at 12 months after surgery, 36.9% were smoking. Sixty percent of patients who lapsed did so during the first 2 months after surgery. Smoking at follow-up was predicted by shorter quit duration before surgery, more intense Appetitive cravings (expectation of pleasure from smoking), lower income, and having a higher level of education. Time until the first smoking lapse was predicted by shorter quit duration before surgery, more intense Appetitive cravings to smoke, and lower income. Among those who lapsed, greater delay before the lapse was associated with abstinence at the 12-month follow-up assessment. Conclusions: Nearly half of non-small-cell lung cancer patients return to smoking after surgery if they have recent smoking histories. Most initial lapses happen within 2 months and occur in response to more recent smoking and more intense cravings. Findings suggest that interventions to prevent relapse should target those who wait until cancer surgery to quit smoking and should be started as soon as possible after treatment.

AB - Background: Non-small-cell lung cancer patients who continue to smoke after cancer diagnosis are more likely to experience disease recurrence, decreased treatment efficacy, and treatment complications. Despite this, many continue to smoke, with estimates ranging from 13% to -60%. Methods: Participants were 154 early-stage, non-small-cell lung cancer patients who had smoked within 3 months before surgery. Patients were followed for 12 months after surgery to assess smoking status and duration of continuous abstinence after surgery. Predictors included medical, smoking history, psychosocial, and demographic characteristics. Results: At some point after surgery, 42.9% of patients smoked; at 12 months after surgery, 36.9% were smoking. Sixty percent of patients who lapsed did so during the first 2 months after surgery. Smoking at follow-up was predicted by shorter quit duration before surgery, more intense Appetitive cravings (expectation of pleasure from smoking), lower income, and having a higher level of education. Time until the first smoking lapse was predicted by shorter quit duration before surgery, more intense Appetitive cravings to smoke, and lower income. Among those who lapsed, greater delay before the lapse was associated with abstinence at the 12-month follow-up assessment. Conclusions: Nearly half of non-small-cell lung cancer patients return to smoking after surgery if they have recent smoking histories. Most initial lapses happen within 2 months and occur in response to more recent smoking and more intense cravings. Findings suggest that interventions to prevent relapse should target those who wait until cancer surgery to quit smoking and should be started as soon as possible after treatment.

UR - http://www.scopus.com/inward/record.url?scp=33846018393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846018393&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0509

DO - 10.1158/1055-9965.EPI-06-0509

M3 - Article

C2 - 17132767

AN - SCOPUS:33846018393

VL - 15

SP - 2370

EP - 2377

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -